[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360413-105":59,"doc-detail-360413-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","real-world-efficacy-of-metronomic-chemotherapy-in-advanced-breast-cancer-across-molecular-subtypes","Real-World Efficacy of Metronomic Chemotherapy in Advanced Breast Cancer Across Molecular Subtypes","","Metronomic chemotherapy (mCHT) is widely used for breast cancer due to low toxicity and convenient administration, yet real-world evidence in advanced disease remains limited. This study assigned patients to a capecitabine-based (X-based) group or other mCHT regimens, extracting baseline, treatment, and outcomes from medical records. Among 597 patients with 35.9 months median follow-up, X-based therapy improved progression-free survival, and as salvage therapy showed superior PFS and overall survival in HR+HER2- patients, especially with endocrine therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-efficacy-of-metronomic-chemotherapy-in-advanced-breast-cancer-across-molecular-subtypes/360413/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-efficacy-of-metronomic-chemotherapy-in-advanced-breast-cancer-across-molecular-subtypes/360413.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of this real-world study?","Question",{"text":112,"@type":113},"To evaluate real-world efficacy of metronomic chemotherapy in advanced breast cancer across molecular subtypes, with emphasis on capecitabine-based regimens versus other mCHT approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients grouped and what outcomes were analyzed?",{"text":117,"@type":113},"Patients were assigned to a capecitabine-based (X-based) group or other mCHT group based on medical records. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier estimates.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about capecitabine-based metronomic chemotherapy?",{"text":121,"@type":113},"With a median follow-up of 35.9 months, the X-based group showed significantly higher median PFS than the other mCHT group. As salvage therapy, it improved PFS and OS in HR+HER2- patients, particularly when combined with endocrine therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360413,1790226804,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Cancer Medicine  \n|  RESEARCH ARTICLE  OPEN ACCESS \u003Cbr>Real-World Efficacy of Metronomic Chemotherapy in Advanced Breast Cancer Across Molecular Subtypes\u003Cbr>Hanxing Zhou1,2,3 | Linmin Chen1,2 | Qianyi Lu1,4 | Huailiang Wu1,2  | Kuikui Jiang1,2  | Fei Xu1,2 | Shusen Wang1,2 \u003Cbr>1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Medical Oncology, Sun\u003Cbr>Yat-Sen University Cancer Center, Guangzhou, Guangdong, China | 2Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China | 3Department of Medical Oncology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China | 4Department of Radiology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China\u003Cbr>Correspondence: Shusen Wang ([wangshs@sysucc.org.cn](wangshs@sysucc.org.cn))\u003Cbr>Received: 5 October 2025 | Revised: 9 May 2026 | Accepted: 11 May 2026\u003Cbr>Keywords: advanced breast cancer | capecitabine | maintenance | metronomic chemotherapy | salvage |  |\n| --- | --- |\n| ABSTRACT\u003Cbr>Objective: Metronomic chemotherapy (mCHT) is widely used in the treatment of breast cancer due to its low toxicity and convenience. However, there remain real-world studies with satisfactory samples focusing on mCHT in advanced breast cancer. Methods: Enrolled patients were assigned into capecitabine-based (X-based) group and other mCHT group. Data on baseline characteristics, treatment regimens, and outcomes were extracted from medical records. Kaplan–Meier estimates of progressionfree survival (PFS) and overall survival (OS) were analyzed.\u003Cbr>Results: Totally, 597 patients were included with median follow-up time of 35.9 months. The median PFS for X-base group was significantly higher than that in other mCHT group (8.9 vs. 5.9 months, p = 0.004). As salvage therapy, the X-based group showed significantly higher PFS and OS than the other mCHT group in patients with HR + HER2-breast cancer (p \u003C 0.001 and p = 0.011), especially in those combined with endocrine therapy (ET) . Multivariate Cox analysis revealed that additional ET could reduce the disease progression and death risks (HR = 0.60, 95% CI: 0.44–0.81; HR = 0.66, 95% CI: 0.47–0.93) . In HER2+ and TNBC populations, the median PFS was higher when used as maintenance therapy compared to salvage therapy (16.0 vs. 7.0 months, p \u003C 0.001; 11.0 vs. 5.0 months, p = 0.030) .\u003Cbr>Conclusion: As salvage therapy, mCHT demonstrated significant efficacy advantages in the X-based group compared to the other mCHT group in patients with HR + HER2-breast cancer, especially in those combined with ET. For HER2+ and TNBC patients, mCHT is recommended as maintenance therapy. |  |\n| 1 | Introduction | 80%[2]. In contrast, the 5-year OS rate for patients with distant metastasis is approximately 25%[3] . The evolution of modern |\n| Breast cancer is a significant global health concern, with data | oncology has led to the emergence of various novel therapeutic |\n| from GLOBOCAN 2022 indicating that it ranks second in terms | approaches in clinical practice, which appear to have dimin- |\n| of newly diagnosed cancer cases and fourth in cancer-related | ished the perceived importance of traditional chemotherapy |\n| mortality [1] . However, advancements in early diagnosis and | [4–7] . Nevertheless, the role of chemotherapy remains cru- |\n| comprehensive treatment strategies have significantly improved | cial, as it continues to be incorporated into numerous ongoing |\n| the prognosis for breast cancer patients. The 5-year overall sur- | clinical trials of anti-tumor therapies [8–11] . In particular, for |\n| vival (OS) rate for non-metastatic breast cancer now exceeds | advanced-stage patients, chemotherapy remains the cornerstone |\n| Hanxing Zhou, Linmin Chen and Qianyi Lu authors contributed equally. |  |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits us","cbCairVQ4uPevnIW","https://ap.wps.com/l/cbCairVQ4uPevnIW","pdf",1697119,"English","# Introduction\n## Metronomic chemotherapy rationale and background\n# ABSTRACT\n## Objective\n## Methods\n## Results\n## Conclusion","[{\"question\":\"What was the main objective of this real-world study?\",\"answer\":\"To evaluate real-world efficacy of metronomic chemotherapy in advanced breast cancer across molecular subtypes, with emphasis on capecitabine-based regimens versus other mCHT approaches.\"},{\"question\":\"How were patients grouped and what outcomes were analyzed?\",\"answer\":\"Patients were assigned to a capecitabine-based (X-based) group or other mCHT group based on medical records. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier estimates.\"},{\"question\":\"What did the study find about capecitabine-based metronomic chemotherapy?\",\"answer\":\"With a median follow-up of 35.9 months, the X-based group showed significantly higher median PFS than the other mCHT group. As salvage therapy, it improved PFS and OS in HR+HER2- patients, particularly when combined with endocrine therapy.\"}]","Real-World Efficacy of Metronomic Chemotherapy in Advanced Breast Cancer Across Molecular Subtypes | PDF",1790140002,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81e3fee6966472fefa5896a324ae46a4.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/081041e549264e9e61fb58267015af32.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff2c2463cdf9aeed57d751602415ef01.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b24e08ded1d515c50fa00ccef4ec0a4.webp",980,1287]